1. Medtech Insight
  2. >>Policy & Regulation

Timing On User Fee Votes Up In Air, As GOP Delays Senate Health Care Bill Battle

 
• By Sue Darcey

Senate leaders had shoved a floor vote on the five-year device and drug user fee reauthorization bill to the back burner to make room for a pre-July 4 vote on the Senate's Obamacare repeal bill, the Better Care Reconciliation Act. But Senate Majority Leader Mitch McConnell is now delaying a vote to get more votes, a step that could further throw off the timing of FDARA passage.

MT1610_StackedCoinsFEES_1200x675

Consideration of a five-year user fee bill, the FDA Reconciliation Act, was pushed back in the Senate's schedule, as Senate Majority Leader Mitch McConnell, R-Kent., announced June 27 he needs more time – until after the July 4th recess – to gather Republican votes in favor of the Senate's Affordable Care Act repeal effort released June 22, the Better Care Reconciliation Act (BCRA). (Also see "ACA Repeal: A Look At Device Procedure Impacts" - Medtech Insight, 16 June, 2017.)

Senate Republicans have recognized the importance of getting the user fee package, FDARA, completed and signed by President Trump before a July 30 deadline, when FDA managers would have to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.